The results of a pilot study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that electro stimulation of one of the nerves connecting the brain to the body (the vagus nerve), could provide a novel treatment approach for patients with rheumatoid arthritis.
“This is a really exciting development. For many patients suffering from rheumatoid arthritis, current treatments don’t work, or aren’t tolerated,” said Professor Thomas Dörner, Chairperson of the Scientific Programme Committee, EULAR. “These results open the door to a novel approach to treating not only rheumatoid arthritis, but other chronic inflammatory diseases. This is certainly an area for further study.”
The vagus nerve is the longest and the most complex of the 12 pairs of cranial nerves that originate from the brain. The name ‘vagus’ comes from the latin word for ‘wandering’. This is because the vagus nerve wanders from the brain into the organs of the neck, chest and abdomen.
Recent advances in neuroscience and immunology have mapped circuits in the brain that regulate immune responses. In one of the circuits, the ‘inflammatory reflex’, signals are transmitted in the vagus nerve that inhibit the production of cytokines including tumor necrosis factor (TNF), an inflammatory molecule that is a major therapeutic target in rheumatoid arthritis. It is thought that, by stimulating the activity of this inflammatory reflex, innate immune responses can be modulated without abolishing them or producing significant immunosuppression.
In this pilot study, a novel miniaturised neurostimulator called a MicroRegulator was implanted into 14 patients with rheumatoid arthritis who had failed on at least two biologics or targeted oral therapies with different mechanisms of action. Patients were randomised to three groups who were either placebo, stimulated once daily, or stimulated four times a day for 12 weeks. At the end of the study, the patients who received once-daily stimulation were shown to have a better response than those on four-times-daily stimulation with two thirds meeting the EULAR good or moderate response criteria and a mean change in DAS28-CRP of -1.24. The mean change in DAS28-CRP* in the placebo group was 0.16.1
Cytokines (a broad and loose category of small proteins that are important in cell signalling) were also measured in the study with the actively stimulated groups showing a decrease of more than 30% in levels of Interleukin (IL) 1?, IL-6, and TNF-?. Implantation and stimulation were generally well tolerated with no device or treatment-related SAEs and two surgery-related adverse events that resolved without clinically significant effects.
“Our pilot study suggests this novel MicroRegulator device is well tolerated and reduces signs and symptoms of rheumatoid arthritis,” said Mark Genovese, M.D., James W. Raitt Endowed Professor of Medicine, Stanford University, Stanford, California, USA. “These data support the study of this device in a larger placebo-controlled study as a novel treatment approach for rheumatoid arthritis and possibly other chronic inflammatory diseases.”
This study follows a proof-of-concept study which used reprogrammed epilepsy stimulators on the vagus nerve to demonstrate reduced systemic inflammation and improved disease activity in 17 patients with rheumatoid arthritis.
The study included 14 patients with active rheumatoid arthritis who had had an insufficient response to more than two biological disease modifying anti-rheumatic drugs (bDMARDs) or JAK inhibitors with more than two modes of action. All patients remained on stable background of methotrexate. The first three patients were implanted and stimulated after three weeks, following safety review board approval, the remaining 11 patients were implanted and randomised to one minute of stimulation once-daily, one minute of stimulation four times daily, or one minute of placebo stimulation.
The Latest on: Electro stimulation
via Google News
The Latest on: Electro stimulation
- Biomarker May Flag Response to Novel AF Interventionon November 26, 2020 at 11:02 am
Neuromodulation of the tragus nerve using a TENS-type device has been shown to reduce AF burden. A biomarker, neuropeptide Y, may flag who will or won't respond to this intervention.
- Spinal Cord Stimulation (SCS) Market Size, Share and Research Analysis to Register Considerable Growth By 2023on November 26, 2020 at 8:39 am
Market Size and Analysis maintains enhanced dynamics and is overshadowed by a top player across the globe. The research report provides Spinal Cord Stimulation (SCS) Market Growth and information ...
- Report Study : Impact of COVID-19 on the Global Pelvic Floor Electrical Stimulation Devices Marketon November 25, 2020 at 11:23 am
The pelvic floor electrical stimulation devices market will reflect a very impressive 9% CAGR for the period of projection between 2020 and 2030. "With rising hospital-based treatments for ...
- UPMC colorectal surgeon offers unique stim treatmenton November 19, 2020 at 4:00 pm
Jasneet Bhullar, MD, MS, FACS, FASCRS, colorectal surgeon, UPMC Williamsport, offers patients an innovative latest electro-stimulation treatment option for diarrhea and bowel incontinence. InterStim† ...
- Functional Electrical Muscle Stimulator Market Analysis 2020, Growth Opportunities, Trends, Forecast to 2020on November 18, 2020 at 5:05 pm
The MarketWatch News Department was not involved in the creation of this content. Nov 18, 2020 (The Expresswire) -- The report “Functional Electrical Muscle Stimulator Market” in Global to 2026 - ...
- The COVID-19 Impact: Pelvic Floor Electrical Stimulation Devices Market Future Growth Insights 2020 to 2030on November 18, 2020 at 12:22 pm
The new report on the Pelvic Floor Electrical Stimulation Devices market provides estimations of the size of the global market and ...
- Mobile Device Offerings Gain Traction in Pelvic Floor Electrical Stimulation Devices Market, Owing to Cost and Portability Benefits: Fact.MR Reporton November 17, 2020 at 7:16 am
Pelvic floor electrical stimulation devices manufacturers are leveraging the growing demand for non-invasive therapeutic solutions for incontinence and sexual dysfunction, over surgical alternatives.
- Liberate Medical Reports Positive Pilot Trial Results of VentFree™ Respiratory Muscle Stimulatoron November 16, 2020 at 6:03 am
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ...
- Pelvic Floor Electrical Stimulation Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030on November 10, 2020 at 3:10 am
utm_source=GNW The report provides the overall market revenue of the global pelvic floor electrical stimulation devices market for the period 2018–2030, considering 2019 as the base year and ...
- Electrical stimulation reduces swallowing problems in patients with neurological conditionson November 9, 2020 at 4:00 pm
In response to this, a group of experts carried out PHADER - the largest-ever study testing whether electrical stimulation of the back of the throat (pharynx), using a treatment catheter ...
via Bing News